Cohen G A, Goffinet J A, Donabedian R K, Conn H O
Ann Intern Med. 1976 Mar;84(3):275-80. doi: 10.7326/0003-4819-84-3-275.
Serum glutamic oxalacetic transaminase (SGOT) activity may be decreased or even absent in patients with uremia. We correlated urea concentration with SGOT activity by the automated Rush (AutoAnalyzer, Techicon Instruments Corp., Tarrytown, New York) method (SGOT, SMA) and by the Henry-Karmen kinetic assay (SGOT, K). Extremely low SGOT (SMA) activity (less than 10 IU) was found in 6% of 5030 consecutive samples, and 71% of them occurred in patients with azotemia. SGOT activity was inversely proportional to urea concentration. A similar but less obvious pattern was observed with the SGOT (K) assay. SGOT activity increased significantly after hemodialysis in a group of 16 patients studied by both methods. It was not inhibited either by urea or uremic serum added in vitro. The explanation for this phenomenon is not known.
尿毒症患者的血清谷氨酸草酰乙酸转氨酶（SGOT）活性可能降低甚至消失。我们通过自动Rush法（AutoAnalyzer，Techicon Instruments Corp.，纽约塔里敦）（SGOT，SMA）和亨利-卡门动力学测定法（SGOT，K）将尿素浓度与SGOT活性进行关联。在连续5030个样本中，6%发现SGOT（SMA）活性极低（低于10 IU），其中71%出现在氮质血症患者中。SGOT活性与尿素浓度呈反比。用SGOT（K）测定法观察到类似但不太明显的模式。通过两种方法研究的一组16例患者在血液透析后SGOT活性显著增加。体外添加尿素或尿毒症血清均未抑制其活性。这种现象的原因尚不清楚。
